William Blair Issues Negative Forecast for Certara Earnings

Certara, Inc. (NASDAQ:CERT) – Stock analysts at William Blair reduced their Q2 2025 earnings per share (EPS) estimates for Certara in a research report issued on Thursday, February 27th. William Blair analyst M. Smock now forecasts that the company will earn $0.06 per share for the quarter, down from their previous forecast of $0.07. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Certara’s current full-year earnings is $0.28 per share. William Blair also issued estimates for Certara’s Q1 2026 earnings at $0.08 EPS, Q2 2026 earnings at $0.07 EPS, Q3 2026 earnings at $0.10 EPS and Q4 2026 earnings at $0.07 EPS.

Several other equities analysts also recently commented on CERT. Stephens reissued an “overweight” rating and issued a $17.00 price objective on shares of Certara in a research note on Thursday, February 27th. TD Cowen assumed coverage on Certara in a report on Thursday, February 27th. They set a “buy” rating and a $16.00 price objective on the stock. Barclays upped their price objective on Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a research note on Friday, February 28th. Finally, Robert W. Baird cut their target price on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Certara currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.83.

Certara Stock Performance

Certara stock opened at $11.85 on Monday. The stock has a market cap of $1.91 billion, a PE ratio of -59.25, a P/E/G ratio of 9.29 and a beta of 1.57. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara has a 12-month low of $9.41 and a 12-month high of $19.87. The business’s 50-day moving average price is $12.50 and its two-hundred day moving average price is $11.63.

Hedge Funds Weigh In On Certara

A number of hedge funds have recently bought and sold shares of the company. Venturi Wealth Management LLC grew its holdings in Certara by 839.1% during the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock worth $30,000 after acquiring an additional 2,509 shares during the period. Wells Fargo & Company MN lifted its stake in Certara by 48.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock valued at $34,000 after buying an additional 1,047 shares during the period. Johnson Financial Group Inc. bought a new position in shares of Certara during the 4th quarter worth approximately $47,000. Blue Trust Inc. increased its stake in shares of Certara by 20.9% in the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock valued at $56,000 after acquiring an additional 822 shares in the last quarter. Finally, KBC Group NV increased its stake in shares of Certara by 48.2% in the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock valued at $57,000 after acquiring an additional 1,584 shares in the last quarter. Institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.